Business Description
R&G PharmaStudies Co Ltd
ISIN : CNE100005K44
Share Class Description:
SZSE:301333: Class ACompare
Compare
Traded in other countries / regions
301333.China IPO Date
2022-08-02Description
R&G PharmaStudies Co Ltd is a clinical trial outsourcing service provider. It offers full-chain clinical research outsourcing services, serving global pharmaceutical and medical device companies and scientific research institutions.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 122.83 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.08 | |||||
Interest Coverage | 145.09 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 6.38 | |||||
Beneish M-Score | -1.11 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.2 | |||||
3-Year EBITDA Growth Rate | 17.4 | |||||
3-Year EPS without NRI Growth Rate | 10.3 | |||||
3-Year FCF Growth Rate | 104.6 | |||||
3-Year Book Growth Rate | 59.6 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 17.06 | |||||
9-Day RSI | 20.76 | |||||
14-Day RSI | 25 | |||||
6-1 Month Momentum % | -30.23 | |||||
12-1 Month Momentum % | -14.78 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.9 | |||||
Quick Ratio | 5.72 | |||||
Cash Ratio | 4.93 | |||||
Days Inventory | 44.51 | |||||
Days Sales Outstanding | 47.1 | |||||
Days Payable | 34.66 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.73 | |||||
Dividend Payout Ratio | 0.12 | |||||
Forward Dividend Yield % | 0.59 | |||||
5-Year Yield-on-Cost % | 0.73 | |||||
3-Year Average Share Buyback Ratio | -10.1 | |||||
Shareholder Yield % | 0.86 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 40.06 | |||||
Operating Margin % | 19.27 | |||||
Net Margin % | 21.25 | |||||
FCF Margin % | 24.03 | |||||
ROE % | 9.23 | |||||
ROA % | 7.7 | |||||
ROIC % | 39.2 | |||||
ROC (Joel Greenblatt) % | 370.47 | |||||
ROCE % | 10.32 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 16.9 | |||||
PE Ratio without NRI | 16.85 | |||||
Shiller PE Ratio | 31.03 | |||||
Price-to-Owner-Earnings | 24.46 | |||||
PEG Ratio | 2.76 | |||||
PS Ratio | 4.18 | |||||
PB Ratio | 1.85 | |||||
Price-to-Tangible-Book | 1.96 | |||||
Price-to-Free-Cash-Flow | 17.25 | |||||
Price-to-Operating-Cash-Flow | 15.48 | |||||
EV-to-EBIT | 8.93 | |||||
EV-to-EBITDA | 8.93 | |||||
EV-to-Revenue | 2.16 | |||||
EV-to-FCF | 8.69 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.42 | |||||
Price-to-Graham-Number | 1.21 | |||||
Price-to-Net-Current-Asset-Value | 2.05 | |||||
Price-to-Net-Cash | 2.59 | |||||
Earnings Yield (Greenblatt) % | 11.2 | |||||
FCF Yield % | 5.41 |